333 related articles for article (PubMed ID: 28754600)
1. Building blocks for institutional preparation of CTL019 delivery.
McGuirk J; Waller EK; Qayed M; Abhyankar S; Ericson S; Holman P; Keir C; Myers GD
Cytotherapy; 2017 Sep; 19(9):1015-1024. PubMed ID: 28754600
[TBL] [Abstract][Full Text] [Related]
2. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
3. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
4. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
6. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
7. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
Liu J; Zhong JF; Zhang X; Zhang C
J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
[TBL] [Abstract][Full Text] [Related]
9. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
[TBL] [Abstract][Full Text] [Related]
11. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
Gill S; June CH
Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
[TBL] [Abstract][Full Text] [Related]
12. A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.
Lu TL; Pugach O; Somerville R; Rosenberg SA; Kochenderfer JN; Better M; Feldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):209-218. PubMed ID: 27897048
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
14. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
Park JH; Geyer MB; Brentjens RJ
Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
[TBL] [Abstract][Full Text] [Related]
15. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
Lorentzen CL; Straten PT
Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
[TBL] [Abstract][Full Text] [Related]
16. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
Wada F; Jo T; Arai Y; Kitawaki T; Mizumoto C; Kanda J; Nishikori M; Yamashita K; Nagao M; Takaori-Kondo A
Sci Rep; 2022 Nov; 12(1):18696. PubMed ID: 36333521
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy in Hematology.
Ataca P; Arslan Ö
Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
[TBL] [Abstract][Full Text] [Related]
18. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
[TBL] [Abstract][Full Text] [Related]
19. Driving CAR-based T-cell therapy to success.
Jena B; Moyes JS; Huls H; Cooper LJ
Curr Hematol Malig Rep; 2014 Mar; 9(1):50-6. PubMed ID: 24488441
[TBL] [Abstract][Full Text] [Related]
20. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
Nakazawa Y
Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]